{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:33:09Z","timestamp":1751463189055,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,21]]},"DOI":"10.1182\/blood.2020005492","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:31:10Z","timestamp":1590075070000},"page":"1822-1823","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Sensitizing Burkitt lymphoma to EBV-CTLs"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E.","family":"Heslop","sequence":"first","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020052111304664300_B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019004126","article-title":"Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral-directed immunotherapy","author":"Dalton","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2020052111304664300_B2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2020052111304664300_B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020052111304664300_B4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"8","key":"2020052111304664300_B5","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3324\/haematol.2018.207548","article-title":"Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease","volume":"104","author":"Kazi","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"2020052111304664300_B6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020052111304664300_B7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol Ther"},{"issue":"1","key":"2020052111304664300_B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020052111304664300_B9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020052111304664300_B10","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/21\/1822\/1731366\/bloodbld2020005492c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/21\/1822\/1731366\/bloodbld2020005492c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:31:32Z","timestamp":1590075092000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/21\/1822\/455325\/Sensitizing-Burkitt-lymphoma-to-EBVCTLs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005492","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2020,5,21]]}}}